ME01592B - Fuzionisani derivati tiazola kao inhibitori kinaze - Google Patents

Fuzionisani derivati tiazola kao inhibitori kinaze

Info

Publication number
ME01592B
ME01592B MEP-2013-70A MEP7013A ME01592B ME 01592 B ME01592 B ME 01592B ME P7013 A MEP7013 A ME P7013A ME 01592 B ME01592 B ME 01592B
Authority
ME
Montenegro
Prior art keywords
kinase inhibitors
thiazole derivatives
fused thiazole
substituted
derivatives
Prior art date
Application number
MEP-2013-70A
Other languages
English (en)
Inventor
Rikki Peter Alexander
Pavandeep Singh Aujla
Karen Viviane Lucile Crépy
Anne Marie Foley
Richard Jeremy Franklin
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Priority claimed from PCT/GB2008/002194 external-priority patent/WO2009001089A1/en
Publication of ME01592B publication Critical patent/ME01592B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Serije   derivata  6,7-di hidro [1,3] tia zolo[5,4-c] piridin -4(5H)-on,  i njihovi  analo zi ,  koji su supstituisani na poziciji  2  sa ponekad supstituisanim ostatkom   morfolin -4- il ,  a koji su selektivni  inhibitor i   encima  PI3 kina za ,  pokazuju potencijalnu medicinsku korist ,  na   primer   u   tretman u poremećaja zapaljenja,  auto - imun og ,  k ardiovas k ular n ih , neurodegenerativ n ih , metaboli čk ih , on k olo šk ih , nociceptiv n ih  ili  o f talm ičkih  poremećaja .
MEP-2013-70A 2006-06-26 2008-06-24 Fuzionisani derivati tiazola kao inhibitori kinaze ME01592B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents
PCT/GB2007/002390 WO2008001076A1 (en) 2006-06-26 2007-06-26 Fused thiazole derivatives as kinase inhibitors
EP08775774A EP2170906B1 (en) 2006-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors
PCT/GB2008/002194 WO2009001089A1 (en) 2007-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
ME01592B true ME01592B (me) 2014-09-20

Family

ID=38671000

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2013-70A ME01592B (me) 2006-06-26 2008-06-24 Fuzionisani derivati tiazola kao inhibitori kinaze

Country Status (20)

Country Link
US (3) US8242116B2 (me)
EP (2) EP2035436B1 (me)
CN (1) CN101687885B (me)
AT (1) ATE510840T1 (me)
AU (1) AU2008269577B2 (me)
CA (1) CA2692085C (me)
CO (1) CO6270229A2 (me)
CY (1) CY1114419T1 (me)
DK (1) DK2170906T3 (me)
EA (1) EA017187B1 (me)
ES (2) ES2365258T3 (me)
HR (1) HRP20130523T1 (me)
IL (1) IL202659A0 (me)
ME (1) ME01592B (me)
MX (1) MX2009013740A (me)
MY (1) MY148852A (me)
PL (1) PL2170906T3 (me)
PT (1) PT2170906E (me)
RS (1) RS52824B (me)
WO (1) WO2008001076A1 (me)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
MX2010010975A (es) 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
WO2010011871A2 (en) * 2008-07-23 2010-01-28 The Regents Of The University Of California Methods and compositions for providing salicylic acid-independent pathogen resistance in plants
WO2010027002A1 (ja) * 2008-09-05 2010-03-11 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
EP2398810A1 (en) 2009-02-17 2011-12-28 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
US20120022057A1 (en) * 2009-03-18 2012-01-26 Schering Corporation Bicyclic compounds as inhibitors of diacyglycerol acyltransferase
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP5554833B2 (ja) 2009-05-20 2014-07-23 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのチアゾロピリミジノン誘導体
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
PL2467387T3 (pl) 2009-08-20 2015-08-31 Karus Therapeutics Ltd Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu
EP2513117B1 (en) 2009-12-18 2013-08-28 Janssen Pharmaceutica, N.V. Bicyclic thiazoles as allosteric modulators of mglur5 receptors
CA2782947A1 (en) 2009-12-18 2011-06-23 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mglur5 receptors
EP2582693B1 (de) 2010-06-15 2016-03-30 Bayer Intellectual Property GmbH Neue ortho-substituierte arylamid-derivate
US20130184320A1 (en) 2010-10-01 2013-07-18 Basf Se Imine Compounds
UY33671A (es) * 2010-10-13 2012-04-30 Millenium Pharmaceuticals Inc Heteroarilos y sus usos
BR112013012961A2 (pt) * 2010-11-24 2019-09-24 Exelixis Inc benzoxazepinas como inhibidores de mtor e métodos de seu uso e fabricação
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
KR20160035613A (ko) 2011-03-23 2016-03-31 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
LT2794600T (lt) 2011-12-22 2018-02-26 Novartis Ag 2,3-dihidro-benzo[1,4]oksazino dariniai ir giminingi junginiai kaip fosfoinozitido-3 kinazės (pi3k) inhibitoriai, skirti gydymui, pavyzdžiui, reumatoidinio artrito
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
CA2903264A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
EP2970132B1 (en) 2013-03-14 2020-09-23 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US20160031839A1 (en) 2013-03-14 2016-02-04 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
EP2970134B1 (en) 2013-03-14 2018-02-28 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
KR102325919B1 (ko) * 2013-10-21 2021-11-12 우미코레 아게 운트 코 카게 방향족 아민의 모노아릴화
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
WO2020056269A1 (en) 2018-09-13 2020-03-19 Stemline Therapeutics, Inc. Methods for treating centronuclear myopathy
US11377425B1 (en) 2018-12-19 2022-07-05 Leo Pharma A/S Small molecule modulators of IL-17
AU2020207089A1 (en) * 2019-01-08 2021-06-24 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508471D0 (en) 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents

Also Published As

Publication number Publication date
US8242116B2 (en) 2012-08-14
EP2035436B1 (en) 2011-05-25
RS52824B (me) 2013-10-31
HRP20130523T1 (en) 2013-07-31
ATE510840T1 (de) 2011-06-15
US20130079330A1 (en) 2013-03-28
CN101687885B (zh) 2012-08-22
MY148852A (en) 2013-06-14
US20110003785A1 (en) 2011-01-06
CO6270229A2 (es) 2011-04-20
CN101687885A (zh) 2010-03-31
WO2008001076A1 (en) 2008-01-03
PL2170906T3 (pl) 2013-08-30
EA201000038A1 (ru) 2010-06-30
PT2170906E (pt) 2013-06-25
ES2365258T3 (es) 2011-09-27
EP2170906A1 (en) 2010-04-07
CA2692085C (en) 2015-10-13
AU2008269577A1 (en) 2008-12-31
EP2035436A1 (en) 2009-03-18
US8338592B2 (en) 2012-12-25
EA017187B1 (ru) 2012-10-30
EP2170906B1 (en) 2013-04-03
ES2416364T3 (es) 2013-07-31
US20100137302A1 (en) 2010-06-03
DK2170906T3 (da) 2013-06-24
AU2008269577B2 (en) 2012-12-20
CY1114419T1 (el) 2016-08-31
MX2009013740A (es) 2010-02-01
US8710054B2 (en) 2014-04-29
IL202659A0 (en) 2010-06-30
CA2692085A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
HRP20130523T1 (en) Fused thiazole derivatives as kinase inhibitors
GB0508471D0 (en) Therapeutic agents
NO20083739L (no) Tieno-pyridinderivater som MEK-inhibitorer
WO2009081105A3 (en) Quinoxaline and quinoline derivatives as kinase inhibitors
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
WO2010052448A3 (en) Fused pyrazine derivatives as kinase inhibitors
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
SMT201600089B (it) Composti di 3,4-diidropirazino[2,3-b]pirazin-2(1 h)-one come inibitori di chinasi mtor per indicazioni oncologiche e malattie associate al percorso mtor/p13k/akt
WO2006098961A3 (en) Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity
EP3489238B8 (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
HK1164866A1 (zh) 作為蛋白質激酶抑制劑的吡咯 吡啶衍生物
TN2018000416A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
AP2011005975A0 (en) Thieno [2,3-B] pyridine derivatives as viral replication inhibitors.
NO20060279L (no) Thienopyridonderivater som kinaseinhibitorer
HK1134486A1 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4,3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders plk1 45--[124][43- f]
MX2009012595A (es) Derivados de espiroindolinona.
PL2794600T3 (pl) Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
PL3436463T3 (pl) Postaci krystaliczne półwodzianu 2-[(2s)-1-azabicyklo[2.2.2]okt-2-ylo]-6-(3-metylo-1h-pirazol-4-ilo)tieno[3,2-d]pirymidyn-4(3h)-onu
PT2124944E (pt) Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
ZA201100437B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazine derivatives as met kinase inhibitors
EP3976607A4 (en) SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AND PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS PROTEIN KINAS INHIBITORS
UA99469C2 (ru) Конденсированные производные тиазола как ингибиторы киназы
IL299758A (en) History of 7-(piperidin-1-yl)-4H-pyrimidio[2,1-B]pyridazin-4-one as positive allosteric modulators of the M4 muscarinic acetylcholine receptor
SG11202100337RA (en) Imidazo[1,2-b]pyridazine derivatives as trk inhibitors
ZA201105257B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyrimidine derivatives